Press Releases
FinVolution Launches 11th Global AI Competition: Teaching Voice AI When to Speak
SHANGHAI, May 22, 2026 (GLOBE NEWSWIRE) -- FinVolution Group has officially launched the 2026 FinVolution Global Data Science Competition. This year's challenge focused on turn-taking modeling in conversations, with the aim of giving voice AI a sense of when to speak.
Aberdeen Investments and DigitalBridge Acquire Equans Infra & Mobility, B.V.
BUNNIK, Netherlands--(BUSINESS WIRE)--A vehicle controlled by DigitalBridge Group, Inc. (NYSE: DBRG) (“DigitalBridge”) and Aberdeen Investments has acquired Equans' asset-based e-mobility activities in the Netherlands. The business specialises in delivering reliable, scalable, and sustainable e-mobility infrastructure. As part of the transaction, the business will be transferred to an entity controlled by DigitalBridge and Aberdeen Investments and will operate under the new name Velian. The new...
Aegon appoints Jennifer Palmieri as Chief Human Resources Officer
Schiphol, May 22, 2026 - Aegon today announces that Jennifer Palmieri will join Aegon as Chief Human Resources Officer and member of Aegon's Executive Committee, effective June 29, 2026. She will succeed Holly Waters who will retire as of June 1, 2026.
Caledonia Mining Corporation Plc: Refiling of Bilboes Gold Project Feasibility Study National Instrument 43-101 Technical Report
(NYSE AMERICAN: CMCL; AIM: CMCL; VFEX: CMCL) SAINT HELIER, JE / ACCESS Newswire / May 22, 2026 / On November 24, 2025, Caledonia Mining Corporation Plc (the "Company") filed the "Bilboes Gold Project Technical Report Summary" with effective date October 31, 2025 prepared by DRA Projects (Pty) Ltd ("DRA") on EDGAR as an exhibit to a Form 6-K Report of Foreign Private Issuer (the "Feasibility Study"). In accordance with Canadian securities regulations, the Company then filed on January 6, 2026 the "Bilboes Gold Project Feasibility Study National Instrument 43-101 Technical Report" with effective date October 31, 2025 prepared by DRA on SEDAR+ (the "Canadian Report ")...
InterContinental Hotels Group PLC Announces Transaction in Own Shares - May 22
LONDON, UK / ACCESS Newswire / May 22, 2026 / The Company announces that on 21 May 2026 it purchased the following number of its ordinary shares of 20340/399 pence each through Goldman Sachs International ("GSI") on the London Stock Exchange in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 8 May 2025 (the "Purchase"). The Purchase was effected pursuant to instructions issued by the Company on 17 February 2026, as announced on 17 February 2026...
OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer
OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi in Recurrent Ovarian Cancer Topline results to be presented by Alexandra Leary, MD, PhD, on May 30, 2026, at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago OSE Immunotherapeutics to host a KOL webcast on June 10, 2026 Nantes, France, May 22, 2026 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today announced the release of the abstract selected for an oral presentation at the upcoming ASCO 2026Annual Meeting, unveiling topline results from the TEDOVA/GINECO-OV244b/ENGOT-ov58 academic, international, Phase 2 trial sponsored by ARCAGY-GINECO and evaluating Tedopi (OSE2101), with or without pembrolizumab, as a maintenance treatment in patients with platinum-sensitive recurrent ovarian cancer (PSOC). Alexandra Leary, MD, PhD, Deputy Head of the Department of Medical Oncology at Gustave Roussy (Paris, France), oncologist specialising in gynaecological cancers, Chair of the GINECO group and Lead Investigator of the TEDOVA Phase 2 clinical trial of Tedopi, commented: “Ovarian cancer (OC) patients treated with platinum sensitive relapse post bevacizumab and PARP-inhibitors represent an unmet medical need with a progression free survival (PFS) of less than 3 months post platinum-based chemotherapy...
LTM Has Issued an Offer to Acquire Randstad's Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services
MUMBAI, India--(BUSINESS WIRE)---- $LTM #AItransformation--LTM has issued an offer to acquire Randstad's Technology and Consulting Services business in Europe and Australia.
NervGen Announces Pricing of US$60.0 Million Public Offering of Securities
VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other neurotraumatic and neurologic conditions, today announced the pricing of an underwritten public offering of 24,000,000 common shares and accompanying warrants to purchase up to 24,000,000 common shares. The common shares are being sold at a public offering price of US$2.50 per common share and accompanying warrant. Each accompanying warrant has an exercise price of US$3.68 per common share, and will be immediately exercisable from the date of issuance, and will expire five years from the date of issuance...
Yimutian Inc. Announces Submission of Hearing Request to Nasdaq and Proactive Measures to Regain Full Compliance
BEIJING, May 21, 2026 (GLOBE NEWSWIRE) -- Yimutian Inc. (Nasdaq: YMT) (“Yimutian” or the “Company”), a leading agricultural digital service company in China, today announced that it has formally submitted a hearing request to the Hering Panel (the “Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) on May 20, 2026, Eastern Time...
Mitsubishi Electric Engineer Earns Kaggle Competitions Master Title in World's Largest AI Competition
TOKYO--(BUSINESS WIRE)--Mitsubishi Electric Corporation (TOKYO: 6503) announced today that Tadakiyo Seki, an engineer at the company's Engineering and Development Center in Japan, has been awarded the title of Kaggle Competitions Master by Kaggle, Inc., a Google LLC subsidiary and the world's largest AI competition platform. The title is awarded based on the total number of medals a competitor accumulates. Kaggle medals recognize competitors who use superior skills in mathematical modeling or m...
Medline Inc. announces pricing of upsized secondary offering of Class A common stock
NORTHFIELD, Ill., May 21, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today the pricing of its upsized secondary offering of 72,554,594 shares of Medline Inc.'s Class A common stock by certain selling stockholders affiliated with Blackstone Inc., Hellman & Friedman LLC and a wholly owned subsidiary of the Abu Dhabi Investment Authority (the “Selling Stockholders”) at a price to the public of $37.00 per share. The Selling Stockholders have also granted the underwriters a 30-day option to purchase up to an additional 10,883,189 shares of Medline's Class A common stock. The offering is expected to close on May 28, 2026, subject to customary closing conditions...
iA Financial Group Announces Offering of $500 million of 4.158% Fixed/Floating Unsecured Subordinated Debentures
QUEBEC CITY--(BUSINESS WIRE)--iA Financial Group (the “Company”) announced today an offering of $500 million aggregate principal amount of 4.158% fixed/floating unsecured subordinated debentures (the “Debentures”) due May 26, 2036 (the “Offering”). The Offering is expected to close on or about May 26, 2026. The Company intends to use the net proceeds from the sale of the Debentures for general corporate purposes, which may include investments in subsidiaries and repayment of indebtedness. The D...
AIFA Provides Update on Nasdaq Notice and Filing of Annual Report, Clearing Key Pathways for Strategic Transformation
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- All In FutureTech Alliance, Inc. (Nasdaq: AGAE) (the “Company” or “AIFA”) today provided an update regarding the previously received notice from the Listing Qualifications Department of The Nasdaq Stock Market.
Liminatus Pharma Announces Nasdaq Delisting Notification
FULLERTON, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that the Company received a delisting notice from The Nasdaq Stock Market LLC (“Nasdaq”).
Peyto Exploration & Development Corp. Announces Voting Results From Annual General Meeting of Shareholders
CALGARY, Alberta, May 21, 2026 (GLOBE NEWSWIRE) -- Peyto Exploration & Development Corp. (TSX – PEY) ("Peyto") is pleased to announce that the nominees listed in the information circular – proxy statement dated April 2, 2026 were elected as directors of Peyto at Peyto's annual meeting of shareholders (the "Meeting") held on May 21, 2026. The detailed results of the votes for the election of directors, the appointment of auditors and the advisory vote on executive compensation held at the Meeting are set out below...
NexgenRx Announces Solid Q1 2026 Results with Continued Increasing Revenue, Net Income and EBITDA Growth
TORONTO, ON / ACCESS Newswire / May 21, 2026 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its financial results for the first quarter ended March 31, 2026, with net income of $1,228,288 and EBITDA of $1,444,036, representing increases of $701,078 and $615,635, respectively, compared to the same period in 2025...
Purecore Engages HEG & Associates for its 2026 Exploration Program at the Bankier Property
VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- Purecore Metals Inc. (CSE: PURE) (“Purecore” or the “Company”) is pleased to announce that it has engaged HEG & Associates Exploration Services Inc. (“HEG”) to plan and execute the Company's 2026 exploration program at the Bankier Property, located in the Similkameen and Osoyoos Mining Divisions of southern British Columbia. About HEG HEG is a Kelowna-based geological services company specializing in exploration programs throughout the Okanagan region and similar geological settings...
Rocket Lab Awarded $90M Contract to Build GEO Satellites Hosting Space Domain Awareness Payload for U.S. Space Force
LONG BEACH, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Rocket Lab Corporation (Nasdaq: RKLB) a leading launch and space systems company, today announced it has been awarded a $90 million contract by the U.S. Space Force's Space Systems Command (SSC) to design, manufacture, integrate, and operate two geostationary (GEO) satellites hosting the Heimdall space domain awareness (SDA) payload...
Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026
ROCKVILLE, Md. and SUZHOU, China, May 21, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced that six abstracts from its clinical studies, selected for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, are now available on ASCO's official website. Three of the six studies have been selected for rapid oral presentations, and three as poster presentation. These abstracts report data from ongoing studies evaluating the company's three lead drug candidates, including BCR-ABL inhibitor olverembatinib(HQP1351); Bcl-2 inhibitor lisaftoclax (APG-2575); and MDM2-p53 inhibitor alrizomadlin (APG-115)...
HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting
HONG KONG and FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the American Society of Clinical Oncology (“ASCO”) Annual Meeting taking place from May 29 to June 2, 2026 in Chicago, USA...
2026 ASCO Abstract Highlights | Innovent Announces Preliminary PoC data of IBI363 (PD-1/IL-2α-bias bispecific fusion protein) in Combination with Chemotherapy as First-line Treatment for Advanced NSCLC, Showing Encouraging Efficacy Signals and Favorable S
SAN FRANCISCO and SUZHOU, China, May 21, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, first announced the preliminary PoC clinical study results for its global first-in-class PD-1/IL-2α-bias bispecific fusion protein IBI363 (Takeda R&D code: TAK-928) in the first-line treatment of advanced non-small cell lung cancer (NSCLC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. An overview of the abstract information is provided below, and the full abstract is available here...
2026 ASCO Abstract Highlights: Innovent Biologics' IBI363 (PD-1/IL-2α-bias bispecific fusion protein) Demonstrates Robust Survival Benefits in Long-Term Follow-up of PoC Study in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
SAN FRANCISCO and SUZHOU, China, May 21, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces updated data from the Phase 1 PoC clinical study of its first-in-class PD-1/IL-2α-bias bispecific fusion protein IBI363 (Takeda R&D code: TAK-928) in the treatment of advanced immunotherapy(IO)-resistant non-small cell lung cancer (NSCLC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. An overview of the abstract information is provided below, and the full abstract is available here...
Lenovo Group: Q4 and Full Year Financial Results 2025/26
HONG KONG--(BUSINESS WIRE)--Lenovo Group Limited (HKSE: 992) (ADR: LNVGY), together with its subsidiaries (‘the Group'), today reported fourth quarter and full year results for fiscal year 2025/26, marking an exceptional Q4 and the strongest year in the Group's history. During the quarter, overall Group revenue reached an all-time fourth quarter high of US$21.6 billion, up 27% year-on-year, marking the highest year-on-year growth rate in five years, with adjusted net income[1] doubling year-on-...
Jeremiah Smith Appointed to Sierra College Foundation Board of Directors
DIXON, Calif.--(BUSINESS WIRE)--First Northern Bank is proud to announce that President and Chief Executive Officer Jeremiah Smith has been appointed to the Board of Directors of the Sierra College Foundation. The Sierra College Foundation supports student success and educational advancement through scholarships, programs, and community partnerships that help create opportunities for students throughout the region. As a member of the Board of Directors, Smith will help support the Foundation's...
Burtech Acquisition Corp II Announces Pricing of $80,000,000 Initial Public Offering
CORAL GABLES, Fla.--(BUSINESS WIRE)--Burtech Acquisition Corp II (the “Company”), a newly organized special purpose acquisition company formed as a Cayman Islands exempted company, today announced the pricing of its initial public offering of 8,000,000 units at an offering price of $10.00 per unit, with each unit consisting of one Class A ordinary share and one redeemable warrant. Each whole warrant, which becomes exercisable 30 days after the completion of the Company's initial business combin...
Hofseth BioCare ASA: EXCLUSIVE LICENSE AND SUPPLY AGREEMENT SIGNED FOR PROGO FOR OVER $5M
Hofseth BioCare ASA (“HBC”) has entered into an Exclusive License and Supply Agreement (the “Agreement”) with Fission Holdings LLC (“Fission”), a US-based affiliate and sales channel operator headquartered in Tulsa, Oklahoma. The Agreement grants Fission exclusive worldwide rights to import, market, distribute, and sell HBC's ProGo salmon-derived bioactive peptide ingredient within the Affiliate, Network Marketing, and Multi-Level Marketing (MLM) channel...
Carolina Financial Services Group Tackles Retirement's “Double Threat”: How Tax and Healthcare Risks Impact Retirees
Greenville, NC, May 21, 2026 (GLOBE NEWSWIRE) -- Carolina Financial Services Group, a Registered Investment Advisor firm with more than 30 years of experience in the Greenville and eastern North Carolina region as well as in the entire East Coast, is addressing the critical need for retirees to mitigate taxation and healthcare costs through a specialized, tech-enabled planning process...
Swiss Water Reports Voting Results from Annual General and Special Meeting of Shareholders
VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- Swiss Water Decaffeinated Coffee Inc. (TSX : SWP) (“Swiss Water” or “the Company”), a leading specialty coffee company and premium green coffee decaffeinator, is pleased to announce the following voting results of the Company's Annual General and Special Meeting of Shareholders, which was held on Thursday, May 21, 2026...
Licensing Expo Concludes with Record-Breaking Show Floor and Participation from Cultural Icons, Cementing Status as Global Epicenter for Brand Collaboration
LAS VEGAS, May 21, 2026 (GLOBE NEWSWIRE) -- Informa Markets' Licensing Expo , the world's most influential event for licensing, IP extension, and brand collaborations, concluded today following three days of unparalleled industry activity at the Mandalay Bay Convention Center. The 2026 edition delivered the largest number of exhibiting companies on record, with 410 exhibitors representing more than 5,000 brands and drawing registered professionals from across the global licensing ecosystem...
VVC Exploration Corporation Provides Regulatory Update and Clarifies a Previous Incorrect Statement about CYRB
TORONTO, May 21, 2026 (GLOBE NEWSWIRE) -- VVC Exploration Corporation, dba VVC Resources (“VVC” or the “Company”) (TSX-V: VVC and OTCQB: VVCVF) is providing an update to its previous news release dated May 16, 2026, regarding the status of its annual financial filings. The Ontario Securities Commission (the "OSC") has notified the Company that its application for a Management Cease Trade Order ("MCTO") has been rejected...
Silverco Mining Files NI 43-101 Technical Report for the Cusi Project PEA
Vancouver, British Columbia--(Newsfile Corp. - May 21, 2026) - Silverco Mining Ltd. (TSXV: SICO) (OTCQB: SICOF) ("Silverco" or the "Company") announces that, in connection with its news release dated April 13, 2026, it has filed on SEDAR+ a National Instrument 43-101 Technical Report titled "Preliminary Economic Assessment Cusi Project, Chihuahua, Mexico" (the "Technical Report"), with an effective date of March 31, 2026...
American Hotel Income Properties REIT LP Announces Annual and Special Meeting of Unitholders
VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- American Hotel Income Properties REIT LP (“AHIP”, or the “Company”) (TSX: HOT.UN, TSX: HOT.U, TSX: HOT.DB. V) announced today that the board of directors of AHIP's general partner (the “Board”) has called an annual and special meeting of unitholders of AHIP (“Unitholders”) to be held on June 18, 2026 (the “Meeting”). The information circular and voting-related materials for the Meeting are being mailed to Unitholders and are also available under AHIP's profile on SEDAR+ at www.sedarplus.ca and on AHIP's website at https://www.ahipreit.com...
Psyence Group Inc. Announces Results of Annual General and Special Meeting of Shareholders
TORONTO, ON / ACCESS Newswire / May 21, 2026 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company") is pleased to announce the voting results from its annual general and special meeting of shareholders held today (the "Meeting"). At the Meeting, shareholders approved all matters brought before the Meeting, including matters relating to the Company's previously announced proposed amalgamation transaction involving Psyence Therapeutics Corp., a wholly owned subsidiary of the Company, and GoldCoast Resource Corp. ("GoldCoast") (the "Transaction")...
ePlus Announces Fourth Quarter and Fiscal Year 2026 Earnings Release Date and Conference Call
HERNDON, Va., May 21, 2026 /PRNewswire/ -- ePlus inc.
AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
- Data from novel Top1i ADC and T-cell engager platforms highlight potential within solid tumors and blood cancers, including oral presentations in prostate cancer, small cell lung cancer, platinum-resistant ovarian cancer and multiple myeloma - NORTH CHICAGO, Ill., May 21, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it will present new data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago demonstrating the depth and breadth of its oncology pipeline...
What drives multimillion-dollar medical claims? Sun Life report shows secondary health conditions, hospital stays and specialty drugs among key factors
WELLESLEY, Mass., May 21, 2026 /PRNewswire/ -- Sun Life U.S. has released its annual High-Cost Claims and Injectable Drug Trends report, which analyzed over 70,000 high-dollar medical claims from more than 3,300 self-funded employers across the country.
As U.S. Markets Continue Roaring to Historic All-Time Highs Like Eagles Above Wall Street, ELEKTROS Celebrates Growing Momentum and Rising Global Awareness Among Penny Stock and Microcap Investors Discovering the Company's Vision for Lithium Mining and Revolutionary EV Patent Technology
WEST PALM BEACH, FL / ACCESS Newswire / May 21, 2026 / As U.S. stock markets continue reaching historic all-time highs and investor appetite for next-generation energy and technology opportunities accelerates across Wall Street, ELEKTROS Inc. (Ticker Symbol:ELEK) announced today that the Company continues aggressively advancing its lithium mining initiatives, electric vehicle charging patent strategy, and broader electrification-focused growth initiatives. Management believes the electrification revolution is accelerating worldwide as lithium demand, EV adoption, and next-generation charging infrastructure continue expanding across global markets...
Credissential Announces Private Placement
CALGARY, AB / ACCESS Newswire / May 21, 2026 / Credissential Inc. ("Credissential" or the "Company") (CSE:WHIP), a vertically integrated AI software development company is pleased to announce a non-brokered private placement financing of up to 3,000,000 units of the Company (the "Units") at a price of $0.16 per Unit for gross proceeds of up to $480,000 (the "Offering"). Each Unit will consist of one common share in the capital of the Company (a "Share") and one-half of one common share purchase warrant (each whole warrant, a "Warrant")...
Midland Exploration Completes a $5.3 Million Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES MONTREAL, May 21, 2026 (GLOBE NEWSWIRE) -- Midland Exploration Inc. (“Midland” or “Corporation”) (TSX-V: MD) is pleased to announce that it has completed a second and final tranche of its previously announced non-brokered private placement by issuing 6,926,123 units of Midland at a price of $0.45 per unit for aggregate gross proceeds of $3.1 million. Each unit consists of one common share and one warrant...
Lightmatter Unveils Guide DR: Industry First Liquid-Cooled Laser NIC that Quadruples Rack Density
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Lightmatter, the leader in photonic (super)computing, today announced Guide DR, a high-density laser in an innovative Laser Network Interface Card (“LNIC”) form factor built to OCP NIC 3.0 dimensions. The Guide DR LNIC is a modular, high-density laser array that enables approximately four times the rack density of conventional External Laser Small Form Factor Pluggables (ELSFPs). By relocating the light source from the faceplate into the chassis, the Gui...
Promino Announces Closing of Final Tranche of Private Placement
Burlington, Ontario--(Newsfile Corp. - May 21, 2026) - Promino Nutritional Sciences, Inc. (CSE: MUSL) (OTCID: MUSLF) (FSE: 93X) ("Promino" or the "Company"), a performance nutrition company focused on clinically validated amino acid formulations, announces that, further to its press releases dated March 13, April 22, May 5, May 15 and May 20, 2026, the Company has closed its final tranche (the "Final Tranche") of its private placement, issuing an aggregate of 3,000,000 units ("Units") at a price of $0.03 per Unit for gross proceeds of $90,000. The Units are composed of one (1) Share and one half of one (1/2) Share purchase warrant, each whole warrant exercisable into one (1) additional Share at a price of $0.06 for one (1) year from the date of issuance...
America's Uranium Corp. Announces Strategic Engagement of Axiom Group and Technical Advisor to Leverage New Geophysical Assessment Results in Ford Lake, Saskatchewan
Vancouver, British Columbia--(Newsfile Corp. - May 21, 2026) - Americas Uranium Corp. (CSE: NUCA) (OTC Pink: ASRFF) (the "Company" or "Americas Uranium") is pleased to announce the advancement in its exploration strategy for the Ford Lake Uranium Project (the "Ford Lake Project") located on the south-eastern edge of the world-renowned Athabasca Basin, Saskatchewan. The company has received a comprehensive geophysical assessment report for the Ford Lake Project, defining high priority structural targets...
PlasCred Circular Innovations Inc. Announces Closing of Second Tranche of Upsized Non-Brokered Private Placement Under Listed Issuer Financing Exemption
Calgary, Alberta--(Newsfile Corp. - May 21, 2026) - PlasCred Circular Innovations Inc. (CSE: PLAS) (FSE: XV2) ("PlasCred" or the "Company") is pleased to announce that, as a result of strong investor demand, it has closed the second tranche (the "Second Tranche") of its previously announced upsized non-brokered $7,000,000 private placement (the "Offering"), issuing 9,746,000 units of the Company (each, a "Unit") at a price of $0.17 per Unit for aggregate gross proceeds of $$1,656,820, pursuant to the listed issuer financing exemption of National Instrument 45-106 - Prospectus Exemptions ("NI 45-106"). Proceeds from the Offering will be used to advance development of the Company's advanced plastic recycling commercial facility ("Neos"), to be located at CN Rail's Scotford Yard in Alberta's Industrial Heartland, including detailed engineering, permitting, procurement of long-lead equipment, and also for general working capital...
Zai Lab Announces Changes to Senior Leadership Team
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced changes to its senior leadership team aimed at strengthening operational performance and efficiency. As part of these changes, the Board has made the decision that Josh Smiley, President and COO, will no longer be with the Company, effective Friday, May 22. "I want to thank Josh for his contributions to Zai Lab over the past three and a half years and wish him well in his future endeavors,"...
CORRECTION – Canadian Banc Corp. Monthly Dividend Declaration for Class A & Preferred Share
TORONTO, May 21, 2026 (GLOBE NEWSWIRE) -- In a prior communication disseminated on May 21, 2026 regarding the May 29, 2026 dividend declaration for BK Class A Shares, the VWAP used to determine the payment rate was not adjusted for the May 19, 2026 Class A Share Split (1.1 for 1). Accordingly, the final dividend payable for the May 29, 2026 record date is $0.16900 per BK Class A Share, revised from the previously disclosed $0.18588. The payment rate is based on 15% of the adjusted VWAP for the last three trading days of the preceding month. The total distributions to date were impacted and have also been amended. No other changes have been made. The corrected release follows:
Universal Technical Institute and Peloton Interactive Set to Join S&P SmallCap 600
NEW YORK, May 21, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, May 27. Universal Technical Institute Inc. (NYSE: UTI) will replace Veris Residential Inc. (NYSE: VRE).
Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting
~ Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations ~
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease
CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Denali Therapeutics Inc. (Nasdaq: DNLI) today announced topline results from the Phase 2b LUMA study evaluating BIIB122 (DNL151), an investigational small molecule inhibitor of LRRK2 (leucine-rich repeat kinase 2), in individuals with early-stage Parkinson's disease. Results from the study show that BIIB122 did not slow the progression of Parkinson's disease versus placebo, as measured by the primary endpoint of Time to Confirmed Worsening in the modified Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II and III combined score. Secondary endpoints also did not show a benefit with BIIB122. Exploratory biomarker endpoints demonstrated >90% kinase inhibition of peripheral LRRK2 (phosphoserine 935) and, in a cerebrospinal fluid (CSF) sub-study, up to approximately 30% reduction observed in a biomarker of LRRK2 activity (phosphorylated Rab10). Expected levels of BIIB122 in the blood and CSF were sustained across the study. BIIB122 was generally well tolerated with an acceptable safety profile. Based on these results, Biogen and Denali will discontinue further development of BIIB122 in idiopathic Parkinson's disease. Denali will continue to independently conduct the Phase 2a BEACON study evaluating the small molecule inhibitor in carriers of a pathogenic LRRK2 variant...
St. Augustine Gold and Copper Limited Announces Board and Management Changes
Manila, Philippines--(Newsfile Corp. - May 21, 2026) - St. Augustine Gold and Copper Limited (TSX: SAU) ("St. Augustine" or the "Company") announces the resignation of Mr. Nicolaos Paraskevas from its board of directors effective May 17, 2026.
OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #ASCO26--OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer.
Prairie Provident Reports on AGM Voting Results
CALGARY, Alberta, May 21, 2026 (GLOBE NEWSWIRE) -- Prairie Provident Resources Inc. ("Prairie Provident" or the "Company") (TSX:PPR) announces voting results from its annual and special shareholders' meeting held today (the “Meeting”). A total of 39,148,743 common shares, representing approximately 83.8% of the Company's issued and outstanding common shares, were represented in person or by proxy at the Meeting...
iwon(TM) Podcast Launches to Challenge the 'Overnight Success' Narrative in SaaS and Tech
London, United Kingdom--(Newsfile Corp. - May 21, 2026) - Michael J. Thomas, founder of DARWIN™ Works Marketing, has launched the iwon™ podcast (It Wasn't Over Night), a long-form series focused on the reality of building software and technology companies beyond the polished success stories often seen online...
Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma
SEATTLE, May 21, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updates on all three of its advancing clinical programs, [²¹²Pb]VMT-α-NET, [²¹²Pb]VMT01, and [²¹²Pb]PSV359, will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place from May 29 to June 2, 2026 in Chicago, IL...
M&T Bank Corporation to Participate in the Morgan Stanley US Financials Conference
BUFFALO, N.Y., May 21, 2026 /PRNewswire/ -- M&T Bank Corporation ("M&T") (NYSE:MTB) will participate in the Morgan Stanley US Financials Conference being held in New York City.
As U.S. Markets Continue Soaring Like Eagles Across Record-Breaking All-Time Highs, ELEKTROS Gains Momentum - Closing Higher Today as Growing Numbers of Penny Stock and Microcap Investors Discover the Company's Vision for Lithium Mining and Advanced EV Patent Technology
WEST PALM BEACH, FL / ACCESS Newswire / May 21, 2026 / As U.S. stock markets continue reaching historic all-time highs and investor appetite for next-generation energy and technology opportunities accelerates across Wall Street, ELEKTROS Inc. (Ticker Symbol:ELEK) announced today that the Company continues aggressively advancing its lithium mining initiatives, electric vehicle charging patent strategy, and broader electrification-focused growth initiatives. Management believes the electrification revolution is accelerating worldwide as lithium demand, EV adoption, and next-generation charging infrastructure continue expanding across global markets...
Conduent Announces Agreement to Sell Its Public Transit Business to Modaxo for $164 Million
FLORHAM PARK, N.J.--(BUSINESS WIRE)--Conduent Incorporated (Nasdaq: CNDT), a global technology‑driven business solutions and services provider, today announced that it has entered into a definitive agreement to sell its Public Transit business, an operating unit of Conduent Transportation, to Modaxo, a global technology organization focused on moving the world's people. The Public Transit business consists of Transit Fare Management and Fleet Management Solutions businesses. The sale has a purc...
Halliburton Announces Dividend
HOUSTON--(BUSINESS WIRE)--Halliburton Company (NYSE: HAL) announced today that its board of directors has declared a 2026 second quarter dividend of seventeen cents ($0.17) a share on the Company's common stock payable on June 24, 2026, to shareholders of record at the close of business on June 3, 2026. About Halliburton Halliburton is one of the world's leading providers of products and services to the energy industry. Founded in 1919, we create innovative technologies, products, and services...
FCPT Announces Acquisition of a Gerber Collision Property for $3.5 Million
MILL VALLEY, Calif.--(BUSINESS WIRE)--Four Corners Property Trust (NYSE:FCPT), a real estate investment trust primarily engaged in the ownership and acquisition of high-quality, net-leased restaurant and retail properties (“FCPT” or the “Company”), is pleased to announce the acquisition of a Gerber Collision property for $3.5 million. The property is located in a highly trafficked corridor in North Carolina and corporate-operated under a triple net lease with approximately eight years of term r...
MSCI Announces Dates for 2026 Annual Market Classification and Accessibility Reviews
NEW YORK--(BUSINESS WIRE)--MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced today that it will release the results of the MSCI 2026 Global Market Accessibility Review on June 18, 2026, and the results of the MSCI 2026 Annual Market Classification Review on June 23, 2026. Both announcements will be made available shortly after 10:30 p.m. Central European Summer Time (CEST) on www.msci.com/market-classificati...
CanCambria Energy Announces Participation in 2026 Louisiana Energy Conference
Vancouver, British Columbia--(Newsfile Corp. - May 21, 2026) - CanCambria Energy Corp. (TSXV: CCEC) (FSE: 4JH) (OTCQB: CCEYF) ("CanCambria" or the "Company") announced today that it will participate in the 2026 Louisiana Energy Conference hosted by Al Petrie Advisors, to be held in New Orleans, Louisiana, on May 26-28, 2026, at the Four Seasons Hotel. Dr. Paul Clarke, Chief Executive Officer, will participate in an International E&P panel discussion on Wednesday, May 27, 2026, at 3:00 p.m...
Modaxo Enters into Agreement to Acquire the Public Transit Business from Conduent
TORONTO, May 21, 2026 (GLOBE NEWSWIRE) -- Modaxo Inc. (“Modaxo”), a global technology organization focused on moving the world's people, today announced that it has signed a definitive agreement to acquire the Public Transit Business, consisting of Transit Fare Management and Fleet Management Solutions businesses, from Conduent Incorporated. Completion of the acquisition remains subject to closing conditions...
nVent to Participate in Upcoming Investor Conference
LONDON, May 21, 2026 (GLOBE NEWSWIRE) -- nVent (NYSE: NVT), a global leader in electrical connection and protection solutions, today announced its participation in William Blairs 46th Annual Growth Stock Conference on Wednesday, June 3, 2026. Beth Wozniak, Chair and Chief Executive Officer, will present at 8:00 a.m. CST...
Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026
SAN DIEGO, May 21, 2026 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that data from Part 1 of the Phase 1b MUIR trial will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 29 – June 2, 2026, in Chicago, Illinois. The poster, titled "Azenosertib Plus Paclitaxel for Platinum-Resistant Ovarian Cancer: Results From a Phase 1b Study," will be presented in the Gynecologic Cancer Poster Session (Abstract #5529, Poster Board #195) on June 1, 2026, from 9:00am–12:00pm CDT...
Manulife Announces Executive Leadership Team Changes
Changes Include Canada Segment, Hong Kong, AI and Data, and Technology and Operations New Team Structure Enables Execution Against Strategic Priorities for Long-term Growth TORONTO, May 21, 2026 /PRNewswire/ - Manulife has announced changes to its executive and senior leadership teams across Canada, Hong Kong, AI and Data, and Technology and Operations to enable sustainable, long-term growth as the company executes its refreshed enterprise strategy. "These important leadership changes ensure we have the right capabilities, both at the enterprise level and in our key markets of Canada and Hong Kong, to achieve our bold ambition and deliver against our new strategic priorities," said Phil Witherington, President and CEO of Manulife...
New Lockheed Martin Facility to Support America's Arsenal of Freedom, Accelerated Production of THAAD Interceptors
Department of War and state officials celebrate groundbreaking in Alabama today TROY, Ala., May 21, 2026 /PRNewswire/ -- Today, Lockheed Martin broke ground on a new Munitions Production Center in Troy, Alabama, marking its latest investment to expand munitions production for the United States and its allies...
Amex Exploration Raises C$59 Million in Total as it Closes Second Tranche of Private Placement
Montreal, Quebec--(Newsfile Corp. - May 21, 2026) - Amex Exploration Inc. (TSXV: AMX) (FSE: MX0) (OTCQX: AMXEF) ("Amex" or the "Company") is pleased to announce that, further to the Company's news release of earlier today, it has closed its non-brokered private placement of 1,622,222 common shares of the Company (the "Common Shares") at a price of $4.50 per Common Share (the "Offering Price") for gross proceeds of C$7,299,999 (the "Non-Brokered Private Placement"). Together with closing earlier today of the Company's "best efforts" private placement of 11,504,161 Common Shares at the Offering Price (the "Brokered Private Placement"), the Company raised aggregate gross proceeds of C$59,068,723.50...
BioInvent Reveals Solid Data with its TNFR2 Antibody BI-1808 and KEYTRUDA(R) (pembrolizumab) in Advanced Ovarian Cancer at ASCO
BioInvent International (STO:BINV) 24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by three the historical single agent activity of 8% in KEYNOTE-100 (2019) 56% disease control rate (DCR) in the combination arm, including multiple durable responses extending beyond 10 months with patients still on treatment The treatment exhibits a very favorable safety profile, and, in contrast to chemotherapy-based regimens, result in very low rates of safety-related treatment discontinuations A preliminary median progression-free survival (mPFS) of 10.3 months in the combination arm, based on early PFS analysis Activity observed across both high-grade serous and clear cell ovarian cancer subtypes Demonstrated robust Treg depletion, reprogramming of myeloid cells, and CD8+ T-cell activation, supporting BI-1808's differentiated mechanism and combination synergy with pembrolizumab Cohort expansion is underway, focusing on high-grade serous and clear cell subtypes, with another data readout expected in H2 2026 LUND, SE / ACCESS Newswire / May 21, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced highly promising early data from its ongoing Phase 2a clinical trial evaluating BI-1808, its monoclonal antibody targeting TNFR2, in combination with MSD's (Merck & Co., Inc., Rahway, NJ., USA) anti-PD-1 therapy KEYTRUDA (pembrolizumab) for the treatment of heavily pretreated patients with advanced ovarian cancer...
Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
ASCEND Phase 1/2 global clinical trial evaluating CR-001 in multiple solid tumor types, including NSCLC, gastrointestinal and gynecological cancers in first-line and previously treated patients Multiple CR-001 clinical data readouts anticipated beginning in Q1 2027 Waltham, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced a trial in progress poster of the ASCEND study of CR-001, a PD-1 x VEGF bispecific antibody, will be presented during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29-June 2, in Chicago...
Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2, 2026...